Isocitrate Dehydrogenase Gene Mutation clinical trials at University of California Health

1 research study open to eligible people

Showing trials for

  • HMPL-306 in Advanced Hematological Malignancies With mIDH

    open to eligible people ages 18 years and up

    An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.

    at UC Irvine

Our lead scientists for Isocitrate Dehydrogenase Gene Mutation research studies include .

Last updated: